Table 2.
Allelic distributions of the NOS2A promoter pentanucleotide microsatellite −2.5 kb (CCTTT)n in IEI patients and healthy subjects.
| Genotype NOS2A −2.5 kb (CCTTT)n |
MCS (N = 170) |
SMCS (N = 108) |
FM/CFS (N = 89) |
Controls (N = 196) |
|---|---|---|---|---|
| 8 | 0.03a | 0.02b | 0c | 0.09 |
| 9 | 0.07 | 0.09 | 0.04 | 0.08 |
| 10 | 0.17 | 0.19 | 0.18 | 0.18 |
| 11 | 0.15 | 0.16 | 0.26d | 0.09 |
| 12 | 0.28 | 0.27 | 0.32 | 0.27 |
| 13 | 0.15 | 0.08 | 0.10 | 0.12 |
| 14 | 0.07 | 0.05 | 0.04 | 0.06 |
| 15 | 0.07 | 0.08 | 0.04 | 0.07 |
| 16 | 0.01e,f | 0.08 | 0.02 | 0.04 |
MCS, multiple chemical sensitivity; SMCS: suspected multiple chemical sensitivity; FM/CFS, fibromyalgia/chronic fatigue syndrome; controls, healthy subjects. a: P = 0.0094, significant difference in comparison with controls; b: 0.0482, significant difference versus controls; c: P = 0.026, significant difference versus controls; d: P = 0.0031, significant difference versus controls; e: P = 0.0426, significant difference versus controls; f: P = 0.0057, significant difference versus SMCS.